Abstract
This paper explores the competing interests between the America Invents Act (AIA) and the patent law’s strict written description requirement. In Part II, this paper will discuss the current first-to-invent system of U.S. patent law and how a first-to-file system under the AIA creates a race to the patent office that spurs competitive behavior. In addition, this section will cover the disclosure requirement of 35 U.S.C. §112, including the decades of case law that formed the strict written description burden on biotechnology. Part III will analyze the competing interest that is created by combining the new patent law with the strict written description requirement. Moreover, this part will illustrate that the conflicting interest will cause disadvantaged biotech inventors to carefully balance their odds of winning the patent race against the need to satisfy strict disclosure. As it will be shown, the scales will tip in favor of filing. Part IV will illustrate the harmful effects of this result, and will explore several possible solutions to mitigate the problem.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
